557. Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients

BACKGROUND: Remdesivir (RDV) has been shown to shorten recovery time and was well tolerated in patients with severe COVID-19. Hydroxychloroquine (HQN) is an experimental treatment for COVID-19. Effects of coadministration of HQN with RDV have not been studied and are relevant given the long half-lif...

Descripción completa

Detalles Bibliográficos
Autores principales: Arribas, Jose Ramon, Sanyal, Arun J, Soriano, Alex, Chin, Bum Sik, Kalimuddin, Shirin, Schreiber, Stefan, Elboudwarej, Emon, Tian, Yuan, Hyland, Robert H, SenGupta, Devi, Chokkalingam, Anand, Osinusi, Anu, Brainard, Diana M, Lübbert, Christoph, Lye, David Chien Boon, Aberg, Judith A, Elorza, Enrique Navas, Tashima, Karen T, McPhail, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776163/
http://dx.doi.org/10.1093/ofid/ofaa439.751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776163/
http://dx.doi.org/10.1093/ofid/ofaa439.751

Ejemplares similares